1. Home
  2. CMU vs LUNG Comparison

CMU vs LUNG Comparison

Compare CMU & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

CMU

MFS Municipal Income Trust

HOLD

Current Price

$3.55

Market Cap

90.0M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.46

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMU
LUNG
Founded
1987
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.0M
72.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CMU
LUNG
Price
$3.55
$1.46
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
67.2K
374.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.08%
N/A
EPS Growth
N/A
10.00
EPS
0.07
N/A
Revenue
N/A
$83,789,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
$51.57
N/A
Revenue Growth
N/A
22.01
52 Week Low
$3.18
$1.31
52 Week High
$3.64
$8.10

Technical Indicators

Market Signals
Indicator
CMU
LUNG
Relative Strength Index (RSI) 45.80 39.58
Support Level $3.48 $1.34
Resistance Level $3.61 $1.93
Average True Range (ATR) 0.04 0.11
MACD -0.00 0.02
Stochastic Oscillator 27.27 24.14

Price Performance

Historical Comparison
CMU
LUNG

About CMU MFS Municipal Income Trust

Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: